Pharmaceutical companies and clinical trial experts will gather in Boston to reinvent the clinical trial process
Online PR News – 10-September-2012 – Boston, MA – Is a zero-delay clinical trial possible? AG Mednet CEO Abraham Gutman thinks so.
Conducting an imaging trial is time-sensitive, expensive and risky. Just one submission error can cost up to seven weeks of trial delay, cost millions of sponsor dollars, and result in the potential loss of patient data. Simply speeding up the system only creates worse results, faster.
Those in attendance will debate whether:
• The current clinical trial system ready for truly disruptive changes that challenge the status quo
• Investigator sites have the right tools to assemble and submit clinical trial data
• The current system allows CROs and AROs to focus on the areas where they bring the most value
Who: AG Mednet CEO Abraham Gutman
What: During the 2nd Annual Disruptive Innovations to Advance Clinical Trials conference, designed for innovative drug development thinkers who are determined to reinvent clinical trials, Gutman will challenge the industry to strive for zero-delay, addressing the current state of the clinical trial ecosystem, common industry misconceptions and the potentially hazardous consequences associated with common assertions.
When: Thursday, September 13th at 4:00 pm
Where: The Fairmont Copley Plaza, Boston, MA
To arrange an interview with Gutman prior to or at the Dpharm conference, please call 781-893-0053 or email email@example.com. For more information about AG Mednet, please visit http://www.agmednet.com/zerodelay/.
About AG Mednet
AG Mednet automates, expedites and improves outcomes in clinical trials by ensuring quality and compliance within critical medical imaging processes. Founded in 2005, AG Mednet is the leading quality compliance partner for image data submission and collection for pharmaceutical, biotechnology and medical device companies, imaging core labs and clinical research organizations managing clinical trials globally. More than 14,000 registered users across thousands of investigator sites in 60 countries use AG Mednet to participate in projects sponsored by each of the world’s top 20 pharmaceutical, biotech and medical device companies.